Back to Search

A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

  • Protocol Number: 202506154
  • Principal Investigator: Weiss, Mia
  • Cancer Types: Sarcoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.

Protocol Interventions

Drug: Zanzalintinib, Drug: Eribulin